OmniActive Health Technologies (OmniActive) has announced the acquisition of ENovate Biolife (ENovate), a developer of proprietary, clinically researched botanical ingredients for health solutions. This deal, financed through internal accruals, reinforces OmniActive's commitment to providing high-quality, scientifically validated health ingredients to global consumers.
Supported by TA Associates, OmniActive has become a leader in safe and effective dietary supplements, utilising advanced encapsulation technologies to enhance ingredient solubility, stability, and bioavailability.
The company aims to double its revenue, reaching Rs 2,000 crores within 5–6 years, from its current Rs1,000 crores, with this acquisition expected to contribute significantly toward that goal. This acquisition follows OmniActive's 2017 purchase of IndFrag, a botanical ingredient company based in Bangalore.
"ENovate's approach aligns perfectly with OmniActive's mission of delivering proven products that make a meaningful difference in consumers' lives," said Sanjaya Mariwala, Executive Chairman and Managing Director of OmniActive. "Their standout ingredients like Muvz, RedNite, and award-winning Oxyjun support our long-term strategy to diversify our portfolio, access new customers and technologies, and expand into new regions."
Jayesh Chaudhary, Founder and CEO of ENovate, added, "We are proud to have formulated clinically backed ingredients for consumer health and performance needs. OmniActive's expertise across clinical research, R&D, regulatory affairs, marketing, and global operations will enhance our ingredients' impact."
OmniActive and ENovate's partnership began in 2019 with a U.S. licensing agreement for enXtra, a clinically studied mental energy ingredient, which has since expanded globally and is now used by numerous premium brands worldwide.